Table 1.

Clinical use of oral fosfomycin in acute and chronic bacterial prostatitis, causative strains, dose regimens, side effects, and outcomes.

Prostatitis Type	Pathogen (n° of Isolates)	Combination Therapy	Fosfomycin Dosage	Adverse Effect	Clinical Cure	Microbiological Cure	Reference
CBP	E. coli (12)	3/12	3 g/24–48 h for 5.5 weeks (mean duration)	Diarrhea (4/12)	Yes	8/12	[1]
	K. pneumoniae (5)	1/5		-	4/5	3/5
	E. coli (14)	1/14	3 g/48–72 h for 6 weeks	-	7/14	8/14	[70]
	K. oxytoca	No			No	No
	E. coli (29)	No	3 g/24 h for the first week, then 3 g/48 h or 3 g/72 h for 6–13 weeks	Diarrhea (4/44)	23/29	23/29	[71]
	K. oxytoca (3)				3/3	3/3
	K. pneumoniae (3)				2/3	2/3
	P. mirabilis (2)				2/2	1/2
	P. aeruginosa				No	No
	E. faecalis (6)				5/6	6/6
	ESBL-E. coli	No	3 g/24 h for 9 days, then 3 g/48 h for 3 months and 3 g/weekly for 9 months	Diarrhea during the first week	Yes	Yes	[72]
	ESBL-E. coli	No	15 weeks of 3 g once daily; 5 days of 3 g twice daily	Diarrhea with the doubled dose	Yes	Yes	[73]
	ESBL-E. coli	Yes	3 g/72 h	-	Yes	Yes	[74]
	E. coli	No	3 g/24 h for 1 week, then 3 g/48 h for 3 months	-	Yes	Yes	[75]
	R. planticola	No	3 g/48 h for 3 months	-	Yes	Yes	[76]
ABP	ESBL-E. coli	No	3 g/24 h for 1 week—3 g/48 h for 2 weeks	Diarrhea during the first week	Yes	Yes	[77]
	ESBL-E. coli	Yes	3 g/24 h—3 g/twice daily (5 days) for 16 weeks	Diarrhea with the doubled dose	Yes	Yes	[73]
	E. faecium	No	3 g/72 h for 3 weeks	-	Yes	Yes	[78]